TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32588401
Drug: Solriamfetol 150
Normalized name: solriamfetol 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 150 mg
Study: 32588401
Drug: Solriamfetol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 300 mg
Study: 34308735
Drug: Zi Gui
Normalized name: Bai jie zi
DrugBank: White mustard seed (DB15606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zi Gui Nv Zhen® capsules (ZGNZC)
Study: 33516752
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl (IPE) 2 grams by mouth twice daily with meals
Study: 32636109
Drug: 10‐mg dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg dexamethasone (2 doses)
Study: 32636109
Drug: 10‐mg dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg dexamethasone (3 doses)
Study: 37903861
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg/day
Study: 36045306
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping with conventional physical therapy (CPT)
Study: 36045306
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CPT) only
Study: 32589977
Drug: Selinexor 60
Normalized name: selinexor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 60 mg orally on days 1 and 3 weekly until disease progression or unacceptable toxicity
Study: 33909232
Drug: Selinexor 60
Normalized name: selinexor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 60 mg
Study: 32456804
Drug: ASP3652 30-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 30-900 mg single dose
Study: 32456804
Drug: ASP3652 100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 100-300 mg BID multiple doses
Study: 34548116
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (stationary cycling) performed daily for 1 week
Study: 34548116
Drug: Non-aerobic exercise
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aerobic exercise (stretching and calisthenics) performed daily for 1 week
Study: 34763506
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy intervention for 4 weeks
Study: 37944025
Drug: Biological mesh
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological mesh
Study: 35966250
Drug: Dapagliflozin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin combined with metoprolol sustained-release tablets (Group A)
Study: 32197277
Drug: Inclisiran (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (300 mg subcutaneous injections on days 1, 90, 270, and 450)
Study: 32197277
Drug: Inclisiran (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (300 mg)
Study: 33066869
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/day)
Study: 32773484
Drug: Universal Testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal Testing and Treatment (UTT)
Study: 33822441
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (0.04 g/kg)
Study: 33430604
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus eptifibatide
Study: 34004189
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin A 5000 IU 3 times weekly for 4 weeks
Study: 34411060
Drug: Droperidol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (20 µg/kg)
Study: 32108686
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 150 µg
Study: 35085017
Drug: Equine-Assisted Activities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine-Assisted Activities and Therapies (EAAT) program conducted for 40 min twice a week for 16 weeks (32 lessons)
Study: 36030106
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg)
Study: 32025814
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg/d) during immobilization and retraining
Study: 32830368
Drug: Abstinence-optimized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence-optimized treatment (A-OT, n = 276)
Study: 35712433
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement
Study: 35712433
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement
Study: 32666172
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered isotretinoin
Study: 32666172
Drug: Combined intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravitreal prophylactic approach of 5-fluorouracil and low molecular weight heparin
Study: 33279182
Drug: Checkpoint inhibitors
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint inhibitors
Study: 36846138
Drug: Low-dose atorvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atorvastatin
Study: 35442486
Drug: Epoetin-alpha plus
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alpha plus insulin therapy (Control)
Study: 33345336
Drug: Methadone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone therapy
Study: 35010932
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera (MO) supplementation (2400 mg/day, 6 capsules daily)
Study: 32504219
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment
Study: 35060229
Drug: Topical triple
Normalized name: Triple Paste Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triple combination (TXA 5% + OXZ 1.5% + BMT 0.33%) applied on the right side of the face
Study: 35060229
Drug: Topical lipocream
Normalized name: Hydrocortisone Butyrate 0.1% Topical Lipocream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lipocream (placebo) applied on the left side of the face
Study: 39501470
Drug: Intravenous tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tirofiban
Study: 32170033
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin 20 mg/kg every 24 hours for 3 days
Study: 32270176
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (reduced from weekly to every other week)
Study: 32270176
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (increased from every other week to weekly)
Study: 32441171
Drug: Rehydration for
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehydration for 60 minutes in 0.9% saline solution
Study: 32100373
Drug: Short day
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short day (SD; 8 L:16 D)
Study: 32100373
Drug: Control (CTR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CTR; 12.5 L:11.5 D)
Study: 34724566
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy
Study: 33568510
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of DNA GTU-MultiHIV B at week 0, 4, and 12, followed by 2 doses of LIPO-5 vaccine at week 20 and 24
Study: 33516464
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation of Bupleurum falcatum L saikosaponins (80 mg/kg of diet)
Study: 33036662
Drug: Ginger-based herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger-based herbal tablets (Vomigone ®) at a dose of 1000 mg three times a day for seven days
Study: 33036662
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for COVID-19 along with Vomigone-like placebo tablets
Study: 33036662
Drug: Ginger-based herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger-based herbal tablets (Vomigone ®)
Study: 35984871
Drug: Ashwagandha (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha (700 mg daily, full spectrum extract of ASH root)
Study: 35213904
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (rectal ibuprofen or intravenous acetaminophen)
Study: 36034411
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment
Study: 32677051
Drug: Ketamine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (single intravenous dose)
Study: 38914481
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound (HIFU) treatment
Study: 36267766
Drug: Kai Hou
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kai Hou Jian (2.5 mL via transoral atomization twice daily for 1 week)
Study: 36267766
Drug: Budesonide (1
Normalized name: budesonide (11.beta.,16.alpha.(S))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1 mg nebulization twice daily for 1 week)
Study: 35054027
Drug: ANI-guided remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANI-guided remifentanil administration
Study: 32945735
Drug: Dried cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried cranberry powder (500 mg)
Study: 33895361
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks
Study: 33895361
Drug: Add-on peginterferon-alpha2b
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-on peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks
Study: 33276811
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy alone (same scheme as in stage 1)
Study: 36097674
Drug: Cabotegravir +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir + rilpivirine LA injections
Study: 33340084
Drug: Fixed implant‐supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed implant‐supported prostheses (FP)
Study: 33340084
Drug: Removable implant‐supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable implant‐supported prostheses (RP)
Study: 32536023
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g 2’FL/LNnT
Study: 32536023
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g 2’FL/LNnT
Study: 36170581
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy combined with pulsed local cryotherapy three times per week for 12 weeks
Study: 36170581
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy three times per week for 12 weeks
Study: 33913678
Drug: PRD-guided remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRD-guided remifentanil administration
Study: 32850394
Drug: Weekly TPF
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly TPF (Docetaxel, Cisplatin, Fluorouracil)
Study: 32850394
Drug: 3-weekly TPF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-weekly TPF (Docetaxel, Cisplatin, Fluorouracil)
Study: 32850394
Drug: Weekly TPF
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly TPF
Study: 38369221
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT)
Study: 35704292
Drug: Intravenous Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Vitamin C (50 mg/kg every 6 hours for up to 96 hours)
Study: 35704292
Drug: Intravenous Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Vitamin C
Study: 32986498
Drug: VenR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VenR with undetectable minimal residual disease (uMRD) at end of combination therapy (EOCT)
Study: 32986498
Drug: VenR followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VenR followed by ibrutinib as first therapy after progression
Study: 34479838
Drug: apalutamide (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: apalutamide (240 mg/d)
Study: 36275396
Drug: Group R
Normalized name: Typhus group rickettsia Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group R (20 ml of 0.33% ropivacaine plus 1 ml normal saline)
Study: 34125374
Drug: Radiation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation and chemotherapy at diagnosis
Study: 35726856
Drug: 0.3 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g·kg‐1 dextrose, identified as creatine (Cr-True)
Study: 35726856
Drug: 0.3 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g·kg‐1 dextrose, identified as creatine (Cr-False)
Study: 35726856
Drug: 0.3 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g·kg‐1 dextrose placebo (PLC)
Study: 33661967
Drug: 10% topical
Normalized name: BP 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% topical diclofenac
Study: 34183350
Drug: Digital cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive-behavioural therapy for insomnia (dCBT-I)
Study: 35218300
Drug: Immediate antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antiretroviral therapy (ART) offered through trial clinics in intervention clusters
Study: 36335970
Drug: Active eradication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active eradication (oral clarithromycin 500 mg, metronidazole 400 mg, and lansoprazole 30 mg, twice daily for 1 week)
Study: 32650801
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection (8 mL)
Study: 32650801
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS) injection (1 mL of 40 mg/mL triamcinolone acetonide plus 5 mL of 2% lidocaine)
Study: 33099944
Drug: Chemotherapy (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (group A)
Study: 32076917
Drug: Sofosbuvir/Daclatasvir (SOF/DCV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir/Daclatasvir (SOF/DCV) therapy
Study: 34010505
Drug: Learning through
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learning through Play Plus (LTP+) added to treatment as usual (TAU)
Study: 34382931
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection then progressive exercise (n=182) (six or fewer physiotherapy sessions)
Study: 34382931
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection then best-practice advice (n=178) (one physiotherapy session)
Study: 33977839
Drug: RIPC C
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIPC C (once daily for 4 weeks)
Study: 33977839
Drug: RIPC D
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIPC D (twice daily for 4 weeks)
Study: 33977839
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no specific sham treatment)
Study: 33594821
Drug: Intermittent TKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent TKI treatment (1 month ON and 1 month OFF)
Study: 34414903
Drug: ivabradine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (5 mg)
Study: 34414903
Drug: metoprolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (25 mg)
Study: 34414903
Drug: ivabradine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (5 mg) and metoprolol (25 mg) combination
Study: 33351303
Drug: Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Undecanoate Capsules (TUC) 40 mg, bid
Study: 33351303
Drug: Jiarong Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiarong Tablets (JRT) + Testosterone Undecanoate Capsules (TUC) 0.92 g, tid
Study: 32539487
Drug: Cognition test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognition test battery administered with a test-retest interval of ≥10 days
Study: 32539487
Drug: Cognition test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognition test battery administered with a test-retest interval of ≤5 days
Study: 32539487
Drug: Cognition test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognition test battery administered 4 times per day
Study: 32212237
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg TID)
Study: 36493691
Drug: Bilateral Electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral Electroconvulsive Therapy (ECT)
Study: 36493691
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (Control)
Study: 33245525
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment in the presence of a therapy dog
Study: 35950596
Drug: Group exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group exercise intervention (twice a week for eight weeks)
Study: 32959058
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (ADE)
Study: 34435439
Drug: Sugammadex (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (doses of 0.125, 0.25, 0.5, 1.0, or 2.0 mg/kg)
Study: 33052757
Drug: Cisplatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (40 mg/m2 weekly during RT)
Study: 33052757
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m2 1 week before RT followed by 250 mg/m2/wk during RT)
Study: 33052757
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation in T3‐T4 tumors
Study: 35841521
Drug: Split-dose PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose PEG
Study: 33356686
Drug: Stepwise dose
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise dose reduction (DR)
Study: 32215805
Drug: Apatinib mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib mesylate 500–750 mg
Study: 36316706
Drug: Logo-therapy intervention
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Logo-therapy intervention (4 sessions of 45-60 min, three times a week)
Study: 36016767
Drug: Oral N-acetyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral N-acetyl cysteine
Study: 32216490
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily vaginal progesterone
Study: 32493502
Drug: Healthy behavior
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy behavior text messaging (daily)
Study: 32493502
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure self‐monitoring (daily)
Study: 36002117
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 5000 mg orally twice daily from D 285 until parturition
Study: 36002117
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 5000 mg lactose orally once daily from D 120 until parturition
Study: 33602439
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT)
Study: 37063970
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after 3-month DAPT
Study: 35596166
Drug: Computer-controlled Intraligamentary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-controlled Intraligamentary anaesthesia (CC-ILA)
Study: 34907594
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg Remimazolam Tosilate (R2)
Study: 33973655
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg intravenous dose of raxibacumab over a period of 2.25 hours
Study: 32886915
Drug: Non-aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aggressive treatment for vasospasm
Study: 35610353
Drug: Structured Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Water Dance Intervention (SWAN), administered for 40 min once a week during a 12-week period.
Study: 33345430
Drug: Sufficient 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient 25(OH)D levels (≥30 ng/mL)
Study: 33831046
Drug: Tocilizumab 400
Normalized name: tocilizumab 400 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 400 mg
Study: 33119467
Drug: 150 mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of fluconazole (EDHF inhibition)